Skip to main content

Advertisement

SpringerLink
Log in

Determining the prognosis of patients with renal cell carcinoma: is it time for a re-evaluation?

  • Viewpoint
  • Published:

From Nature Clinical Practice Urology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A et al. (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10–30

    Article  Google Scholar 

  2. Pantuck AJ et al. (2001) The changing natural history of renal cell carcinoma. J Urol 166: 1611–1623

    Article  CAS  Google Scholar 

  3. Guinan P et al. (1997) TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80: 992–993

    Article  CAS  Google Scholar 

  4. Sobin LH (2003) TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol 21: 19–22

    Article  Google Scholar 

  5. Zisman A et al. (2001) Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol 166: 54–58

    Article  CAS  Google Scholar 

  6. Cindolo L et al. (2005) Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 104: 1362–1371

    Article  Google Scholar 

  7. Kim HL et al. (2004) Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10: 5464–5471

    Article  CAS  Google Scholar 

  8. Leppert JT and Pantuck AJ (2006) Significance of gene expression analysis of renal cell carcinoma. Expert Rev Anticancer Ther 6: 293–299

    Article  CAS  Google Scholar 

  9. Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434

    Article  CAS  Google Scholar 

  10. Motzer RJ et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16–24

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Associate Professor of Urology in the Department of Urology at the Geffen School of Medicine, UCLA, Los Angeles, CA, USA

    John T Leppert & Allan J Pantuck

Authors
  1. John T Leppert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Allan J Pantuck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Allan J Pantuck.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leppert, J., Pantuck, A. Determining the prognosis of patients with renal cell carcinoma: is it time for a re-evaluation?. Nat Rev Urol 3, 510–511 (2006). https://doi.org/10.1038/ncpuro0598

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0598

  • Springer Nature Limited

Search

Navigation